Stay up-to-date on FSR’s latest activities and learn about the ways that FSR is driving progress and accelerating research towards a cure.
FSR launched the Ignore No More: ACTe Now! Campaign (Advance Clinical Trials for Equity in Sarcoidosis) to address the underrepresentation of Black Americans in clinical trials. As part of the campaign, FSR conducted the first of its kind, IRB-approved national patient survey for Black Americans to better understand the challenges and experiences Black Americans with sarcoidosis face as it pertains to clinical trials and their disease journeys. FSR also conducted a Key Opinion Leaders Thought Workshop (KOL) and Patient Focus Group to explore the findings in greater depth and to identify recommendations for how to improve clinical trial access and overall care of Black sarcoidosis patients.
Some recommendations that emerged include building a blueprint for clinical trial design that increases access and supports diversity, clinical trial navigation and support specifically targeted for Black patients, and educational toolkits to better educate patients and physicians about trial opportunities and engagement. Though this campaign was specific to Black Americans with sarcoidosis the learnings are relevant to improving access to clinical trials for all Black Americans.
Toolkits
White Papers
Annual Updates
Press Releases
FSR Blog
How to have a good doctor’s visit
How to have an effective office visit with your provider: Getting the most of your office visits can be tricky, especially if you’reLearn More
Mary’s Anniversary
Mary McGowan’s Reflections on her First Year Anniversary as FSR’s CEO Over the last year, I learned how resilient the FSR community is,Learn More
WHO Air Quality Guidelines Update: Health experts urge nations to implement ambitious air pollution reduction policies
Health experts urge nations to implement ambitious air pollution reduction policies Health experts and patient representative groups have issued a joint statement urging nations toLearn More
aTyr Pharma Announces Positive Data from Phase 1b/2a Pulmonary Sarcoidosis Clinical Trial
On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to haveLearn More
Living with ILD: A Sarcoidosis Patient Perspective
My journey with Interstitial Lung Disease (ILD) started about 15 years ago, although I did not know it at the time, nor did theLearn More
COVID-19 Vaccine Boosters for Immunocompromised Patients
Sarcoidosis does not automatically indicate an immunocompromised diagnosis. FSR cannot determine or provide recommendations for your individual immunocompromised status. Please consult your physician forLearn More
Introducing the FSR Patient Speakers’ Bureau
We are thrilled to announce the formation of our new FSR Patient Speakers’ Bureau! This bureau consists of 14 experienced and trained sarcoidosisLearn More
FSR-MNK Sarcoidosis Research Fellow Awarded for 2021-2023
The Foundation for Sarcoidosis Research (FSR) is pleased to announce the Foundation for Sarcoidosis Research Fellowship Grant for 2021-2023 is being awarded to Dr.Learn More
FSR Welcomes Three New Members to its Board of Directors
The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients,Learn More
Quick links
Check out these recent updates!